Domestic medical insurance status of Ripotinib (Augtyro)

Reputinib, widely known by its trade names Akeral andAugtyro, is a targeted ROS1 kinase inhibitor specifically for patients with ROS1-positive non-small cell lung cancer (NSCLC). This drug effectively inhibits the proliferation and spread of cancer cells by precisely blocking the ROS1 protein, bringing new treatment options to these patients and marking another new breakthrough in the field of precision treatment of non-small cell lung cancer.

Recently, the new progress of Ripotinib in medical insurance has attracted much attention. In the latest 2024 National Medical Insurance Drug Catalog update released by the National Medical Insurance Administration, raptinib is listed and is officially included in the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer. For eligible patients, this decision means that they will be able to enjoy the benefits of medical insurance reimbursement during the treatment process, which will significantly reduce their financial burden and increase the accessibility of treatment.

However, it is worth noting that although reputinib has been included in medical insurance, the specific reimbursement ratio and conditions may vary due to geographical differences. Therefore, before initiating treatment, patients need to proactively consult with local medical insurance institutions or doctors to clarify the specific content of the reimbursement policy and the application process. At the same time, medical insurance reimbursement usually requires patients to meet specific indications and treatment stage conditions.

In addition, for patients with greater financial pressure, the generic version of reputinib launched by Lucius Pharmaceuticals of Laos may provide a more economical treatment option. The generic drug is available in the specifications of 40 mg * 60 tablets and is priced at more than 3,000 yuan, which is more affordable than the original drug. However, when patients consider using generic drugs, they must ensure that they purchase them through formal channels to ensure the safety and efficacy of the drugs.

In summary, the inclusion of repotinib in the national medical insurance directory will undoubtedly bring substantial economic benefits to patients with ROS1-positive non-small cell lung cancer. This policy adjustment not only effectively alleviates patients' financial pressure, but also further improves the accessibility of treatment and brings more treatment hope to patients.

References:

https://www.drugs.com/augtyro.html

xa0